C4 Therapeutics, Inc.

The momentum for this stock is not very good. C4 Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in C4 Therapeutics, Inc..

News

C4 Therapeutics announces delivery of second development candidate to Biogen

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

Globe Newswire Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical...\n more…

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Globe Newswire Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET...\n more…

CCCC Makes Notable Cross Below Critical Moving Average

Market News Video In trading on Tuesday, shares of C4 Therapeutics Inc (CCCC) crossed below their 200 day moving average of 5.99, changing hands as low as 5.72 per share. C4 Therapeutics Inc shares are...\n more…

C4 Therapeutics appoints Stephen Fawell to board of directors

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Globe Newswire WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...\n more…